Peptidyl Arginine Deiminase (PAD) for Proteasome-Mediated Signaling and Neurodegenerative Disorders

Target Name: Peptidyl arginine deiminase (PAD)

NCBI ID: P6349

Peptidyl arginine deiminase (PAD)

Other Name(s): Protein-arginine deiminase | PAD

Peptidyl Arginine Deiminase (PAD) for Proteasome-Mediated Signaling and Neurodegenerative Disorders

Peptidyl Arginine Deiminase (PAD): A Promising Drug Target for Proteasome-Mediated Signaling and Neurodegenerative Disorders

Introduction

Proteasome-mediated signaling is a complex intracellular signaling pathway that plays a pivotal role in cellular homeostasis, development, and disease. It is a highly conserved pathway that involves the degradation of protonated amino acids, such as arginine, as a byproduct of protein synthesis. Unfortunately, aberrant protein-arginine deiminase (PAD) activity has been implicated in the development and progression of numerous neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. As a result, targeting PAD has become an attractive research focus to investigate its potential as a drug target or biomarker.

PAD localizes to the endoplasmic reticulum (ER) and is responsible for the conversion of arginine residues in protein back to its original amino acid, ArG. PAD is a member of the arylalanyl proteinase (AP) family and its primary structure consists of a catalytic core and a transmembrane region. PAD catalyzes the urethylation of arginine residues in the protein tail, which is followed by its conversion to ArG. This reaction is reversible, and PAD can also catalyze the deimination of arginine residues in the protein tail, leading to the formation of urodehydroxy arginine (UDP-arg) and its subsequent conversion to UDP-glucuronate.

PAD is involved in various cellular processes, including cell signaling, DNA replication, and protein folding. It has been shown to be involved in the regulation of cell adhesion, migration, and invasion, as well as in the development and progression of neurodegenerative diseases.

Mutations in the PAD gene have been implicated in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In particular, mutations in the PAD gene have been linked to increased neurodegeneration and the development of neurodegenerative diseases.

Targeting PAD as a drug target has the potential to treat a variety of neurodegenerative disorders. By inhibiting PAD activity, researchers may be able to reduce neurodegeneration and improve overall quality of life in neurodegenerative disease patients. Additionally, targeting PAD may also provide new insights into the underlying mechanisms of neurodegenerative diseases and identify potential new therapeutic targets.

PAD has also been shown to be a potential biomarker for neurodegenerative diseases. The levels of PAD activity in brain tissue can be increased in individuals with neurodegenerative disease, and PAD has been shown to be involved in the regulation of neurodegenerate protein synthesis. Therefore, measuring PAD activity in brain tissue may be a useful biomarker for the diagnosis and progression of neurodegenerative diseases.

In conclusion, PAD is a promising drug target and biomarker for the treatment of neurodegenerative diseases. Further research is needed to fully understand the role of PAD in neurodegenerate disease and to develop effective therapies that target PAD. By inhibiting PAD activity, researchers may be able to improve neurodegeneration and improve overall quality of life in neurodegenerative disease patients. Additionally, by identifying PAD as a biomarker for neurodegenerative diseases, researchers may be able to develop new diagnostic tests and monitor the effectiveness of therapies.

Protein Name: Peptidyl Arginine Deiminase (PAD) (nonspecified Subtype)

The "Peptidyl arginine deiminase (PAD) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Peptidyl arginine deiminase (PAD) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets